Arbutus Biopharma Announcement Today, June 21, 2023, Arbutus Biopharma (ABUS) announced that the first patient has been dosed in the additional treatment arm of the AB-729 Phase 2a triple combination clinical trial, which has been expanded to include a PD-1 monoclonal antibody, nivolumab. Please note that . . . This content is for paid subscribers. Please click here to subscribe or here to log in.